Madison Vaccines Inc. reports that early findings of its prostate cancer vaccine used together with a PD-1 inhibitor (protein) have shown early success against the disease.
The clinical trial on 18 patients at UW–Madison has yielded some positive results including lowering PSA levels, shrinking tumors, and even increasing white blood cells.
Based on the early results, expanded trials are likely.
